GlaxoSmithKline and Pozen, Inc. received FDA approval of Treximet for the treatment of migraine attacks in adults. Treximet is the first migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of GSK’s migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet. The product is expected to be available in U.S. pharmacies by mid-May.     Treximet contains 85 mg sumatriptan, formulated with RT Technology, and 500 mg nap...